[1] |
WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: The major ipact of China[J]. Hepatology, 2014, 60(6): 2099-2108. DOI: 10.1002/hep.27406
|
[2] |
CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338
|
[3] |
WU W, HE X, ANDAYANI D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study[J]. J Cancer, 2017, 8(12): 2312-2318. DOI: 10.7150/jca.19056
|
[4] |
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.008
中华医学会肝病学分会, 中华医学会感染病分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008
|
[5] |
Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
|
[6] |
TAMAKI K, SHIMIZU I, URATA M, et al. A patient with spinal metastasis from hepatocellular carcinoma discovered from neurological findings[J]. World J Gastroenterol, 2007, 13(19): 2758-2760. DOI: 10.3748/wjg.v13.i19.2758
|
[7] |
OKAMOTO H, SHINKAI T, MATSUNO Y, et al. Intradural parenchymal involvement in the spinal subarachnoid space associated with primary lung cancer[J]. Cancer, 1993, 72: 2583-2588. DOI: 10.1002/1097-0142(19931101)72:9<2583::AID-CNCR2820720912>3.0.CO;2-K
|
[8] |
BHATIA R, RAVULAPATI S, BEFELER A, et al. Hepatocellular carcinoma with bone metastases: Incidence, prognostic significance, and management—Single-Center Experience[J]. J Gastrointest Cancer, 2017, 48(4): 321-325. DOI: 10.1007/s12029-017-9998-6
|
[9] |
CARRAT F, FONTAINE H, DORIVAL C, et al. ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study[J]. Lancet, 2019, 393: 1453-1464. DOI: 10.1016/S0140-6736(18)32111-1
|
[10] |
JI FP, ZHANG S, DENG H, et al. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: Further evidence in decompensation cirrhosis[J]. J Hepatol, 2013, 58(6): 1262-1264. DOI: 10.1016/j.jhep.2013.01.041
|
[11] |
JI FP, ZHOU R, WANG WJ, et al. High post-treatment α-fetoprotein levels and aspartate aminotransferase-to-platelet ratio index predict hepatocellular carcinoma in hepatitis C virus decompensated cirrhotic patients with sustained virological response after antiviral therapy[J]. J Interferon Cytokine Res, 2017, 37(8): 362-368. DOI: 10.1089/jir.2017.0040
|